|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500095118 |
|
最近更新日期: Date of Last Refreshed on: |
2025-01-02 09:49:47 |
|
注册时间: Date of Registration: |
2025-01-02 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
胰腺坏死组织感染的诊断、治疗与微生物学:一项多中心、前瞻性、观察性队列研究 |
|
Public title: |
Diagnosis, trEatment and microBiology of infected pancReatic necrosls seconDary to acutE necrotizing pancreatitis: A multicenter, prospective, observational cohort study |
|
注册题目简写: |
胰腺坏死组织感染的诊断、治疗与微生物学:一项多中心队列研究 |
|
English Acronym: |
Diagnosis, trEatment and microBiology of infected pancReatic necrosls seconDary to acutE necrotizing pancreatitis: A multicenter cohort study |
|
研究课题的正式科学名称: |
胰腺坏死组织感染的诊断、治疗与微生物学:一项多中心、前瞻性、观察性队列研究 |
|
Scientific title: |
Diagnosis, trEatment and microBiology of infected pancReatic necrosls seconDary to acutE necrotizing pancreatitis: A multicenter, prospective, observational cohort study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李刚 |
研究负责人: |
柯路 |
|
Applicant: |
Gang Li |
Study leader: |
Lu Ke |
|
申请注册联系人电话: Applicant telephone: |
+86 181 5168 9897 |
研究负责人电话:
Study leader's |
+86 158 5076 8312 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
Leeg871027@163.com |
研究负责人电子邮件: Study leader's E-mail: |
ctgkelu@nju.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省南京市玄武区中山东路305号 |
研究负责人通讯地址: |
江苏省南京市玄武区中山东路305号 |
|
Applicant address: |
No. 305 Zhongshan East Road, Xuanwu District, Nanjing, Jiangsu Province |
Study leader's address: |
No. 305 Zhongshan East Road, Xuanwu District, Nanjing, Jiangsu Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
210000 | |
|
申请人所在单位: |
东部战区总医院 |
||
|
Applicant's institution: |
Jinling hospital |
||
|
研究负责人所在单位: |
东部战区总医院 |
||
|
Affiliation of the Leader: |
Jinling hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024DZKY-027-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
东部战区总医院临床研究伦理委员会 |
||
|
Name of the ethic committee: |
Clinical Research Ethics Committee, General Hospital Of Eastern Theater Command |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-05-27 00:00:00 | ||
|
伦理委员会联系人: |
吴琼 |
||
|
Contact Name of the ethic committee: |
Qiong Wu |
||
|
伦理委员会联系地址: |
江苏省南京市玄武区中山东路305号 |
||
|
Contact Address of the ethic committee: |
No. 305 Zhongshan East Road, Xuanwu District, Nanjing, Jiangsu Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 25 8086 3234 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
东部战区总医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Jinling hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省南京市玄武区中山东路305号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 305 Zhongshan East Road, Xuanwu District, Nanjing, Jiangsu Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
None |
||||||||||||||||||||||
|
研究疾病: |
胰腺坏死感染 |
||||||||||||||||||||||
|
Target disease: |
Infected Pancreatic Necrosis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
进一步明确胰腺坏死感染诊断准确性和病原菌分布情况,探究胰腺坏死感染患者不同抗感染治疗和侵入性干预时机与预后的关系。 |
||||||||||||||||||||||
|
Objectives of Study: |
We aim to further clarify the diagnostic accuracy and distribution of pathogenic bacteria of infected pancreatic necrosis and to investigate the relationship between different antibacterial treatments and the timing of invasive interventions and the prognosis of patients with infected pancreatic necrosis. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 年龄≥18 岁; 2. 胰腺坏死感染或临床疑似感染性坏死,根据《修订的亚特兰大标准》,当影像学检查结果和/或细菌培养结果证实:计算机断层扫描显示胰腺和/或胰周组织中存在气泡,或通过细针穿刺、引流或坏死组织切除术获得的胰腺和/或胰周坏死组织培养阳性,即可诊断为胰腺坏死感染。疑似感染性坏死的定义是:患者出现持续性器官衰竭(呼吸、肾脏、循环)或至少两种炎症指标持续恶化(体温>38.5℃ 、C反应蛋白升高或白细胞升高)超过3天; 3. 签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. age ≥ 18 years; 2. infected or clinically suspected infected pancreatic necrosis, which is diagnosed according to the Revised Atlanta Criteria when imaging findings and/or bacterial culture results confirm: the presence of gas bubbles in the pancreas and/or peripancreatic tissues on computed tomography scan or a positive culture of the pancreas and/or peripancreatic necrotic tissues obtained by fine-needle aspiration, drainage, or necrotic tissue resection. Suspected infectious necrosis was defined as a patient presenting with persistent organ failure (respiratory, renal, circulation) or persistent worsening of at least two markers of inflammation (temperature >38.5°C , elevated C-reactive protein, or elevated white blood cells) for more than 3 days; 3. signed informed consent. |
||||||||||||||||||||||
|
排除标准: |
1. 慢性胰腺炎病史。 2. 在其他医院已行胰腺坏死组织引流、清创或手术 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. History of chronic pancreatitis. 2. Drainage, debridement or surgery of necrotic pancreatic tissue already performed at another institution |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-01 00:00:00至 To 2026-07-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-01-02 00:00:00 至 To 2026-01-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
在主要研究论文发表后,数据库将供所有研究的参与者共享,在获得数据管理委员会批准后,所有参与者均可利用本数据库,进行数据分析和论文写作 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the publication of the primary research paper, the database will be made available to all participants in the study, and with the approval of the Data Management Committee, all participants will be able to utilize the database for data analysis and paper writing. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究将使用基于网络的电子数据库EDC(慧芳,中国,无锡)用于数据采集和管理。所有数据将由主要研究者或主要研究者批准的指定研究者(每个参与中心少于两个)输入。数据录入培训将由研究团队进行。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
A web-based electronic database, EDC (Huifang, Wuxi, China), will be used for data collection and management in this study. All data will be entered by the principal investigator or designated investigators approved by the principal investigator (less than two per participating center). Data entry training will be conducted by the study team. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |